Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HAIC plus regorafenib and PD-1 inhibitor versus regorafenib plus PD-1 inhibitor for second-line hepatocellular carcinoma
ChiCTR2100046555Phase 4Recruiting
- Sponsor
- Army Medical University
- Start
- May 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of regorafenib, camrelizumab, nivolumab and pembrolizumab in hepatocellular carcinoma (HCC) (2 arms), sponsored by Army Medical University. Primary endpoint: Disease remission rate. Started May 2021; status: recruiting.
02
Drugs
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2100046555.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100046555.